Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Skin cancer is the most common cancer in the U.S., with risks influenced by factors like sun exposure, skin type, and income.

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

Nearly a decade after Erin Andrews was diagnosed with cervical cancer, the sportscaster told E! News she can't treat ...

Squamous cell carcinoma is the second most common type of skin cancer, and can be deadly if left untreated. Here are the ...

An 85-year-old man who credits the Lingen Davies Cancer Centre with saving his life is preparing for a final trip to his ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Skin cancer is the most common cancer in the United States and a significant health issue, with millions of non-melanoma ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...